Compared side by side
TB-500 vs Ac-SDKP: how they differ
The short answer
Both come from thymosin beta-4, from different ends: TB-500 is residues 17–23, the stretch that binds actin, and Ac-SDKP is residues 1–4, sold as a “TB-500 fragment” though it isn’t part of TB-500. In rodent studies Ac-SDKP calms inflammation and scarring in the heart, kidneys and lungs and helps new blood vessels form, while TB-500 sped wound repair in aged mice and strengthened repaired tendons in rats. Ac-SDKP is cleared by ACE within minutes, and no study has looked at it for tendons or ligaments.
Side by side
| Compared | TB-500 | Ac-SDKP |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Thymosin Beta-4 Fragment, TB4 | TB-500 Fragment, TB-4 Frag, Goralatide, Thymosin Beta-4 (1-4) |
| What it is | A fragment of thymosin beta-4, a protein your body uses for cell repair. | The first four amino acids of thymosin beta-4, sold as a 'TB-500 fragment' though it isn't part of TB-500. |
| How it works | Synthetic fragment of Thymosin Beta-4: Ac-LKKTETQ, the 7-amino-acid stretch (residues 17–23) that binds actin. The whole protein holds actin building blocks back from forming filaments, a reserve cells draw on when they move. In lab and rodent studies the fragment drew blood-vessel cells, sped wound repair in aged mice and strengthened repaired tendons in rats; the anti-inflammatory findings are for the whole protein. Loading phase 2x/week then drop to maintenance. | Isolated N-terminal tetrapeptide of Thymosin Beta-4, residues 1–4; TB-500 itself is residues 17–23, so this isn't part of TB-500. In rodent and cell studies it is anti-inflammatory and anti-fibrotic in heart, kidney and lung models and promotes angiogenesis and cell migration. It is cleared by ACE within minutes, and ACE inhibitors raise its blood levels about fourfold. |
| Commonly reported | Stubborn soft-tissue injuries loosening up, with range of motion returning over a few weeks. Its own research is a few animal studies; the human trials tested the whole protein. Often paired with BPC-157. | Community data are sparse, and users who report on it describe it much like TB-500, a gradual easing of soft-tissue aches. |
| Studied range | Research range: 1–2.5 mg. Studied in research — not a recommendation. | Research range: 250–750 mcg. Studied in research — not a recommendation. |
| How often | 2x/week loading, 1–2mg/week maintenance | EOD or twice weekly. |
| Half-life | ~0.5–2 hours (measured for the whole protein, thymosin beta-4, given IV to healthy volunteers; TB-500 itself has never been measured in people) | ~4.5 min (measured in healthy volunteers after IV; cleared by ACE, and a SubQ dose peaks in about 15 minutes) |
| Route | SubQ injection, IM injection | SubQ injection |
| Typical run | Loading phase 2x/week for 4–6 weeks, then maintenance 1x/week or stop. Common to cycle 6–8 weeks on, time off. | 6-8 week cycles typical. Preferred over full TB-500 by some for targeted tendon/ligament work. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection site reaction, fatigue, nausea, headache, lethargy | Injection site reaction, fatigue, headache |
- Category
- TB-500Healing & recovery
- Ac-SDKPHealing & recovery
- Also known as
- TB-500Thymosin Beta-4 Fragment, TB4
- Ac-SDKPTB-500 Fragment, TB-4 Frag, Goralatide, Thymosin Beta-4 (1-4)
- What it is
- TB-500A fragment of thymosin beta-4, a protein your body uses for cell repair.
- Ac-SDKPThe first four amino acids of thymosin beta-4, sold as a 'TB-500 fragment' though it isn't part of TB-500.
- How it works
- TB-500Synthetic fragment of Thymosin Beta-4: Ac-LKKTETQ, the 7-amino-acid stretch (residues 17–23) that binds actin. The whole protein holds actin building blocks back from forming filaments, a reserve cells draw on when they move. In lab and rodent studies the fragment drew blood-vessel cells, sped wound repair in aged mice and strengthened repaired tendons in rats; the anti-inflammatory findings are for the whole protein. Loading phase 2x/week then drop to maintenance.
- Ac-SDKPIsolated N-terminal tetrapeptide of Thymosin Beta-4, residues 1–4; TB-500 itself is residues 17–23, so this isn't part of TB-500. In rodent and cell studies it is anti-inflammatory and anti-fibrotic in heart, kidney and lung models and promotes angiogenesis and cell migration. It is cleared by ACE within minutes, and ACE inhibitors raise its blood levels about fourfold.
- Commonly reported
- TB-500Stubborn soft-tissue injuries loosening up, with range of motion returning over a few weeks. Its own research is a few animal studies; the human trials tested the whole protein. Often paired with BPC-157.
- Ac-SDKPCommunity data are sparse, and users who report on it describe it much like TB-500, a gradual easing of soft-tissue aches.
- Studied range
- TB-500Research range: 1–2.5 mg. Studied in research — not a recommendation.
- Ac-SDKPResearch range: 250–750 mcg. Studied in research — not a recommendation.
- How often
- TB-5002x/week loading, 1–2mg/week maintenance
- Ac-SDKPEOD or twice weekly.
- Half-life
- TB-500~0.5–2 hours (measured for the whole protein, thymosin beta-4, given IV to healthy volunteers; TB-500 itself has never been measured in people)
- Ac-SDKP~4.5 min (measured in healthy volunteers after IV; cleared by ACE, and a SubQ dose peaks in about 15 minutes)
- Route
- TB-500SubQ injection, IM injection
- Ac-SDKPSubQ injection
- Typical run
- TB-500Loading phase 2x/week for 4–6 weeks, then maintenance 1x/week or stop. Common to cycle 6–8 weeks on, time off.
- Ac-SDKP6-8 week cycles typical. Preferred over full TB-500 by some for targeted tendon/ligament work.
- Evidence
- TB-500Emerging: primarily preclinical / limited human data
- Ac-SDKPEmerging: primarily preclinical / limited human data
- Common side effects
- TB-500Injection site reaction, fatigue, nausea, headache, lethargy
- Ac-SDKPInjection site reaction, fatigue, headache
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
TB-500
- Day 1–7 Week one: set your baseline
- Day 7–14 Stiffness often starts to ease
- Day 14–28 Load tolerance often picks up
- Day 28–42 Gains slow, repair keeps going
- Day 42–56 Weeks 6 to 8: how far it's come
Ac-SDKP
Week-by-week cards for Ac-SDKP are not in our library.
Together or one or the other
TB-500 and Ac-SDKP are a common stack: Ac-SDKP lists TB-500 among its common stacks.
Questions people ask
How long do TB-500 and Ac-SDKP last?
The half-life of TB-500 is ~0.5–2 hours (measured for the whole protein, thymosin beta-4, given IV to healthy volunteers; TB-500 itself has never been measured in people). The half-life of Ac-SDKP is ~4.5 min (measured in healthy volunteers after IV; cleared by ACE, and a SubQ dose peaks in about 15 minutes).
How often are TB-500 and Ac-SDKP taken?
TB-500: 2x/week loading, 1–2mg/week maintenance. Routes: SubQ injection, IM injection. Ac-SDKP: EOD or twice weekly. Route: SubQ injection.
How are TB-500 and Ac-SDKP dosed in research?
The research range for TB-500 is 1–2.5 mg. The research range for Ac-SDKP is 250–750 mcg. Studied in research — not a recommendation.
What are the common side effects of TB-500 and Ac-SDKP?
For TB-500, the library lists: injection site reaction, fatigue, nausea, headache, lethargy. For Ac-SDKP: injection site reaction, fatigue, headache.
Are TB-500 and Ac-SDKP taken together?
TB-500 and Ac-SDKP are a common stack: Ac-SDKP lists TB-500 among its common stacks.